Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, United States of America.
Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, United States of America.
J Affect Disord. 2022 Jul 1;308:243-248. doi: 10.1016/j.jad.2022.04.033. Epub 2022 Apr 14.
Early markers preceding suicide ideation (SI) may provide valuable information for both assessment and treatment. The glutamatergic modulator ketamine has rapid, transient effects on SI, creating an opportunity to observe potential antecedents of the re-emergence of SI. This analysis evaluated whether the interaction between two suicide risk factors-psychological pain and hopelessness-were prospectively associated with SI post-ketamine administration.
Data were drawn from three ketamine clinical trials of participants with treatment-resistant major depressive disorder or bipolar disorder (n = 108) with short- and/or long-term follow-up (three or 11 days). A random intercept cross-lagged panel model evaluated the longitudinal relationship between the correlated concepts, specifically whether the interaction between hopelessness and psychological pain was associated with future SI.
Psychological pain and hopelessness were not prospectively associated with SI in short-term or long-term analyses; rather, long-term analyses found that SI was associated with later psychological pain and hopelessness. Similarly, no relationship was observed for other suicide risk factors, including anhedonia, depressed mood, and impaired sleep.
Secondary analysis of clinical trial data not collected for this purpose; hopelessness and psychological pain were assessed via proxy measures from existing depression rating scales; the small sample size required a restricted statistical model.
Psychological pain and hopelessness were not associated with the re-emergence of SI post-ketamine. These results may be due to limited variability in the data. The re-emergence of SI post-ketamine may also not follow patterns typically seen in non-pharmacologic contexts. Individuals with a history of SI warrant careful monitoring post-ketamine administration.
自杀意念(SI)出现之前的早期标志物可能为评估和治疗提供有价值的信息。谷氨酸调节剂氯胺酮对 SI 有快速、短暂的影响,为观察 SI 再次出现的潜在前兆提供了机会。本分析评估了两种自杀风险因素——心理痛苦和绝望感之间的相互作用是否与氯胺酮给药后 SI 呈前瞻性相关。
数据来自三项氯胺酮治疗难治性重度抑郁症或双相情感障碍患者的临床试验(n=108),包括短期和/或长期随访(3 天或 11 天)。随机截距交叉滞后面板模型评估了相关概念的纵向关系,特别是绝望感和心理痛苦之间的相互作用是否与未来 SI 相关。
短期或长期分析中,心理痛苦和绝望感均与 SI 无前瞻性相关;相反,长期分析发现 SI 与随后的心理痛苦和绝望感相关。同样,其他自杀风险因素(包括快感缺失、抑郁情绪和睡眠障碍)也未观察到相关性。
对非为此目的而收集的临床试验数据进行二次分析;绝望感和心理痛苦通过现有抑郁评定量表的代理测量来评估;样本量小,需要采用受限的统计模型。
氯胺酮给药后,心理痛苦和绝望感与 SI 的再次出现无关。这些结果可能是由于数据的变异性有限。氯胺酮给药后 SI 的再次出现也可能不符合非药物治疗情况下通常观察到的模式。有 SI 病史的个体在氯胺酮给药后需要密切监测。